Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis.
<h4>Background</h4>Vascular endothelial growth factor tyrosine-kinase inhibitors (VEGFR-TKIs) have emerged as an effective targeted therapy in the treatment of cancer patients, the overall incidence and risk of proteinuria associated these drugs is unclear. We performed a systematic revi...
Saved in:
Main Authors: | Ze-Feng Zhang, Tao Wang, Li-Hua Liu, Hui-Qin Guo |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0090135&type=printable |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Liver function dynamics in advanced hepatocellular carcinoma receiving immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization
by: Chen-You Liu, et al.
Published: (2025-06-01) -
Signaling of Receptor Tyrosine Kinases in the Nucleus
by: Stephenson, Sally-Anne, et al.
Published: (2012) -
Epigenetic Alteration of Receptor Tyrosine Kinases in Cancer
by: Dricu, Anica, et al.
Published: (2012) -
Establishment of in vitro Src tyrosine kinase inhibitors screening model
by: WANG Chen-hui, et al.
Published: (2007-11-01) -
Modern vector in treatment of patients with lung cancer: tyrosine kinase inhibitors in epidermal growth factor receptor mutations (literature review)
by: O.M. Smorodska, et al.
Published: (2021-06-01)